Oncology
Antibodies, antibody-drug conjugates and small molecules in solid tumors and hematologic malignancies.
See programsScience
Our research spans four therapeutic areas. Teams in China and the United States contribute to discovery and the development of medicines for patients.

Antibodies, antibody-drug conjugates and small molecules in solid tumors and hematologic malignancies.
See programsMedicines for immune-mediated conditions, including adalimumab for rheumatoid arthritis.
See programsResearch in lipid disorders, including ongericimab, an antibody targeting PCSK9.
See programsAntiviral medicines, including deuremidevir hydrobromide (VV116) for COVID-19.
See programsJunshi’s platforms connect antibody discovery with development and industrial scale-up. Innovation centers in Shanghai and Suzhou support the process from target discovery through clinical development.
Monoclonal, bispecific and multispecific antibodies are represented in Junshi’s research portfolio.
Junshi is advancing antibody-drug conjugates, including JS212 for selected solid tumors.
Other research programs include small molecules, fusion proteins and nucleic acid medicines.
Explore individual programs by therapeutic area and stage.
View the pipelineFind company-sponsored studies and check registry information.
Find a trialBrowse peer-reviewed articles by medicine and therapeutic area.
Browse publications